Jonker, Leon, Fisher, Stacey Jayne, Westgate, Robert and Overend, Louise (2020) Evaluation of progression to diabetes in high-risk patients eligible to attend the ‘Walking Away from Diabetes’ educational intervention: a retrospective cohort study. British Journal of Diabetes, 20 (1). pp. 15-18.

Downloaded from: http://insight.cumbria.ac.uk/id/eprint/5572/

Usage of any items from the University of Cumbria’s institutional repository ‘Insight’ must conform to the following fair usage guidelines.

Any item and its associated metadata held in the University of Cumbria’s institutional repository Insight (unless stated otherwise on the metadata record) may be copied, displayed or performed, and stored in line with the JISC fair dealing guidelines (available here) for educational and not-for-profit activities provided that

• the authors, title and full bibliographic details of the item are cited clearly when any part of the work is referred to verbally or in the written form
• a hyperlink/URL to the original Insight record of that item is included in any citations of the work
• the content is not changed in any way
• all files required for usage of the item are kept together with the main item file.

You may not

• sell any part of an item
• refer to any part of an item without citation
• amend any item or contextualize it in a way that will impugn the creator’s reputation
• remove or alter the copyright statement on an item.

The full policy can be found here. Alternatively contact the University of Cumbria Repository Editor by emailing insight@cumbria.ac.uk.
Title: Evaluation of long-term diabetes outcomes for high-risk patients eligible to attend the ‘Walking Away from Diabetes’ educational intervention; a retrospective cohort study.

Running title: Long-term outcomes for Walking Away from Diabetes programme.

Authors: L Jonker, S J Fisher, R Westgate, L Overend

#Dr Leon Jonker, PhD; Science & Innovation Manager, Cumbria Partnership NHS Foundation Trust, Research & Development Department, Carlisle, CA1 3SX, UK. Tel 0176824 5975, e-mail leon.jonker@cumbria.nhs.uk [ORCID number 0000-0001-5867-4663]

Dr Stacey Jayne Fisher, MBBS, MRCGP; Research GP, Cumbria Partnership NHS Foundation Trust, Research & Development Department, Carlisle, CA1 3SX, UK, e-mail stacey.fisher@cumbria.nhs.uk

Dr Robert Westgate, MBBS, FRCGP; Medical Director, Carlisle Healthcare, St Paul’s Medical Centre, Carlisle, CA1 1DG, UK. Robert.Westgate@gp-A82016.nhs.uk

Dr Louise Overend, MBBS, FRCP; Consultant diabetologist, Cumbria Partnership NHS Foundation Trust, Diabetes Department, Carlisle, CA2 7HY, UK, e-mail louise.overend@cumbria.nhs.uk

# Author for correspondence

Conflicts of interest: none.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Abstract

**Aims** To retrospectively assess the efficacy of a pragmatic education programme called Walking Away from Diabetes (WAD), a single-session intervention aimed at patients who are at risk of developing type 2 diabetes mellitus (T2DM).

**Methods** Baseline and follow-up data for 6116 patients, identified as ‘at risk of diabetes’ in the period April 2012 to March 2016, were assessed for T2DM status in January 2018. Any differences in outcome between WAD attenders and non-attenders was explored using Kaplan-Meier, Log rank testing and Cox regression analyses.

**Results** During the follow-up period, 426 out of 3470 (12.3%) WAD attenders and 349/2646 (13.2%) non-attenders were diagnosed with T2DM (p-value 0.068, Log rank test). Cox regression shows that HbA1C (hazard ratio [HR] 1.23, p-value <0.001) and HDL levels (HR 0.67, p-value <0.001), rather than WAD attendance (HR 0.89, p-value 0.11), were the main two factors associated with progress from ‘at risk’ to T2DM.

**Conclusions** Although the wider health impact of the WAD programme was not considered here, session attendance does not appear to reduce the risk of developing T2DM. However, other factors influence the risk of developing T2DM. It is essential for educational programmes, designed to have a preventative effect for people at risk of diabetes, to be assessed for short- and long-term efficacy.

**Key Words**: diabetes, education, exercise, lifestyle, patient education, diabetes risk.
Introduction

Lifestyle interventions can enable a reduction in risk of developing T2DM.\textsuperscript{[1,2]} This has been shown in various randomised controlled trials in a variety of populations.\textsuperscript{[1,3,4,5]} The aim of the cited studies was to promote more intense physical activity in conjunction with an improvement in healthy diet adherence and weight management for overweight and obese patients. ‘Walking Away from Diabetes’ (WAD) is a theory driven, structured education programme for people identified at increased risk of T2DM. WAD has been developed within the NHS and is based on a previously published study.\textsuperscript{[6,7,8]}

To date there is only clinical outcome data available on the WAD programme from a controlled clinical trial and one-year follow-up.\textsuperscript{[6]} In that study, WAD did have a statistically significant positive effect on biomedical and lifestyle outcomes. Therefore, investigating the long-term outcomes related to WAD is indicated, to appraise whether WAD intervention impacts on the risk of at risk people progressing to diabetes.

Material & Methods

Study design

This concerns a retrospective cohort study, and is classed as a service evaluation in accordance with UK Health Research Authority guidelines. Therefore, individual informed consent was not obtained from patients to use their data. Caldicott approval was obtained from the NHS Trust that holds the data to analyse and publish it.

WAD programme details
The WAD programme is described in more detail elsewhere.\textsuperscript{[6,8]} In summary, it provides three hours of structured education for up to 10 people (and a partner/friend) led by two trained educators. The programme is aimed at promoting walking and to further enhance the physical activity through walking message, patients are issued with a pedometer to self-monitor the steps they take daily. Other information provided to attendees involve the causes, complications and timelines for glucose intolerance and diabetes. Patient at risk of developing diabetes as determined by Leicester Diabetes Risk Assessment and/or pre-diabetic Hba1c levels (42 to 47 mmol/mol).\textsuperscript{[7]} This study cohort includes patients referred to WAD by GPs between 1 April 2012 and 31 March 2016, and end date for follow-up was 1 January 2018.

Data sources and analysis

Baseline demographic and clinical measures were taken in the GP surgery when a patient was classified as being at risk of diabetes. These included a patient’s residence postcode, sex, age, HbA1C, HDL, cholesterol, and blood pressure. Patient ethnicity was not recorded, but the study sample is from a county in England where 96.5 \% of the population is White British.\textsuperscript{[9]} Index of multiple deprivation deciles were calculated from patients’ postcodes\textsuperscript{[10]}, with 1 being the highest degree of deprivation, and data on T2DM diagnosis was extracted from a national database maintained by the University of Exeter. For continuous and ordinal data, the mean and median, respectively, plus the 95\% confidence interval (95\% CI) was calculated. Differences between WAD attender and non-attender cohorts were assessed with Chi-squared test (binary and nominal data) and Mann-Whitney U-test (ordinal and continuous data). The rate of diagnosis of T2DM over time was considered with a Kaplan-Meier plot accompanied by Log rank test for WAD as a factor on its own, and Cox regression
analysis for all variables. Data was collated using Microsoft Excel and analysed using SPSS v20, and a p-value of 0.05 was considered significant.

Results

Across the period that the WAD programme ran in this particular NHS Trust, a total of 7916 patients were identified as being eligible for attendance in primary care, and referred to the WAD team in the diabetes department. Of those, 4420 patients attended and 3496 did not (56% attendance rate). Complete datasets, baseline demographic, clinical measurements data and diabetes outcome data were available for 6116 people who were identified as being at risk of developing T2DM. Therefore, all further data analysis was conducted using the dataset for these patients. The mean follow-up time was 52.0 months (95% CI 51.4-52.5) for attenders and 48.3 months (95% CI 47.7 – 49.0) for non-attenders (p-value <0.001, Mann-Whitney U-test). In total, 426 out of 3470 (12.3%) attenders and 349/2646 (13.2%) non-attenders were eventually diagnosed with T2DM during the follow-up period. The baseline variable measurements were not identical between the WAD attendance and non-attendance cohorts. Table 1 summarises that they differed in average age, degree of deprivation, HDL level, and cholesterol levels. Those who attended WAD were significantly older, less deprived, and had a better cardiovascular health profile.

When diabetes diagnosis in relation to solely WAD attendance is considered, Log rank analysis and Kaplan-Meier plotting (Figure 1) of diabetes diagnosis cases shows that there is no significant difference in the number of diabetes cases diagnosed during the follow-up period (p-value 0.068, Log rank test). Since this kind of analysis does not take into account any confounding factors that may influence whether someone develops diabetes, Cox
regression analysis was conducted to determine if any variables are associated with diabetes, and if this influences any impact that WAD attendance may have on diabetes developing during the follow-up period. Table 2 shows that HbA1C and HDL levels are associated most significantly with diabetes risk, both in terms of magnitude (hazard ratio [HR]) and statistical significance (p-value). A higher HbA1C level is associated with an increased risk of T2DM, whereas conversely a higher HDL level is associated with a lower risk of developing diabetes. Variables significantly associated with T2DM risk but with a negligible hazard ratio are deprivation score, patient age, and cholesterol. On the other hand, WAD attendance is not significantly linked to the risk of developing diabetes, though there appears to be a trend to lower risk of diabetes if a patient attends a session (not significant at p-value of 0.11).

Discussion

This retrospective evaluative study set out to appraise if real-life application of the WAD programme is significantly associated with a reduction in subsequent T2DM diagnosis in subsequent years. At first sight this does not seem to be the case. However, there are a few caveats to bear mind mind. Although the sample size is large and average follow-up period is considerable, this study is hamstrung by being a retrospective evaluation of the effectiveness of the WAD programme. Consequently, fasting glucose, low-density lipid profiles and some anthropometric measures such as body mass index are not included in the analysis. Neither is any data on pre- and post-attendance exercise levels achieved by people in this cohort; this is where a prospective epidemiological study would be
advantageous. From the available data it is observed that the non-significant reduction seen in T2DM in the WAD attenders can probably be attributed to a multitude of factors. There is a difference in baseline composition of the WAD attenders and non-attenders, both in terms of clinical and non-clinical parameters. Because the patients were able to choose whether to attend or not, rather than being allocated to a specific treatment arm, this could not be controlled for. Both high HbA1C and low HDL levels are recognised risk factors for T2DM as identified in controlled trials and through meta-analysis.\(^{[14,15,16]}\) In absolute terms the average follow-up period for non-attenders is 3.7 months shorter, which equates to a 7% relative difference in follow-up time ‘to the benefit’ of the non-attendance arm. Despite the potential confounding role of HDL and relative difference in follow-up time between attenders and non-attenders, the long-term impact of attending a WAD session on diabetes risk appears modest and inconclusive. This contrasts to a Finnish diabetes prevention programme where short-, medium- and long-term outcomes have been positive.\(^{[1,13]}\) The main difference between the Finnish and WAD programme is the number of times the patient attended an education session: seven sessions with a nutritionist in first year alone vs one single session with a session practitioner, respectively. The achieved attendance rates are similar for both programmes, with a >50% participation rate recorded. In this present study we did not explore the medium- to long-term wider positive impact that the WAD programme may have from a patient-perspective, and therefore one has to be mindful that it may have other unintended positive effects bar prevention of T2DM.

National policy means that the WAD programme has been superseded by the Healthier You: NHS Diabetes Prevention Programme that is rolled out across England, using various programme delivery providers.\(^{[18,19]}\) The limited effectiveness observed in this present
evaluation for the WAD programme may be due to a number of reasons, but the intensity of the intervention may be the key reason. Similar to the Finnish programme on which it is based\textsuperscript{[20]}, the ‘Healthier You’ programme involves at numerous (at least 13) education and exercise sessions of one to two hours each. The potential role of confounding factors – demographic, anthropometric and clinical – should be taken into account when evaluating the new ‘Healthier You’ programme. Early indications are that similar trends are observed as in the WAD cohort, with older, female patients more likely to attend.\textsuperscript{[21]}

**Conclusions**

The single-session WAD education programme may not significantly slow down the rate of T2DM manifesting in people at risk of diabetes. More recent published data suggest that extended and more intense education programmes may be more effective in preventing progression to diabetes. However, evaluations of programmes need to be mindful of confounding variables such as patients’ lipid profiles, and potential non-intended health benefits that a programme may bring.

**References**

1. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–50.
2. Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2005;28:2780–6.
3. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.

4. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005;67:152–62.

5. Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289–97.

6. Yates T, Davies M, Gorely T, Bull F, Khunti K. Effectiveness of a pragmatic education programme aimed at promoting walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. Diabetes care. 2009 Aug;32(8):1404-10.

7. Gray LJ, Taub NA, Khunti K, Gardiner E, Hiles S, Webb DR, Srinivasan BT, Davies MJ. The Leicester Risk Assessment score for detecting undiagnosed type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabetic medicine. 2010 Aug;27(8):887-95.

8. Westgate R, Yates T, Troughton J, Stribling B, Khunti K, Davies MJ. Implementation of a structured education programme aimed at the prevention of Type 2 diabetes within routine primary care: p280. Diabetic Medicine. 2011 Mar 1;28:115.

9. Cumbria Observatory, population data on ethnicity, 2011.
   https://www.cumbriaobservatory.org.uk/population/ (last accessed 3 July 2019)

10. Index of Multiple Deprivation. https://www.gov.uk/government/statistics/english-indices-of-deprivation-2015 (last accessed 3 July 2019)
11. Cost of diabetes care in the UK, Diabetes UK, [https://www.diabetes.co.uk/cost-of-diabetes.html](https://www.diabetes.co.uk/cost-of-diabetes.html) (last accessed 3 July 2019).

12. Ali MK, Echouffo-Tcheugui JB, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program?. Health affairs. 2012 Jan 1;31(1):67-75.

13. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. The Lancet. 2006 Nov 11;368(9548):1673-9.

14. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Utility of hemoglobin A1c in predicting diabetes risk. Journal of general internal medicine. 2004 Dec;19(12):1175-80.

15. Yan Y, North KE, Ballantyne CM, Brancati FL, Chambless LE, Franceschini N, Heiss G, Kottgen A, Pankow JS, Selvin E, West SL. The Atherosclerosis Risk in Communities Study. Diabetes. 2009 Jan;58:285.

16. Look AHEAD Research Group. Long term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes: four year results of the Look AHEAD trial. Archives of internal medicine. 2010 Sep 27;170(17):1566.

17. NICE Public health guideline [PH38], Type 2 diabetes: prevention in people at high risk [https://www.nice.org.uk/guidance/PH38/](https://www.nice.org.uk/guidance/PH38/)
18. NHS Diabetes Prevention Programme

https://www.england.nhs.uk/diabetes/diabetes-prevention/ (last accessed 3 July 2019)

19. Healthier You diabetes prevention programme. https://preventing-diabetes.co.uk/

(last accessed 3 July 2019).

20. Penn L, Rodrigues A, Haste A, Marques MM, Budig K, Sainsbury K, Bell R, Araújo-Soares V, White M, Summerbell C, Goyder E. NHS Diabetes Prevention Programme in England: formative evaluation of the programme in early phase implementation. BMJ open. 2018 Feb 1;8(2):e019467.

21. Barron E, Clark R, Hewings R, Smith J, Valabhji J. Progress of the Healthier You: NHS Diabetes Prevention Programme: referrals, uptake and participant characteristics. Diabetic Medicine. 2018 Apr;35(4):513-8.

3-5 very short Key messages. Abbreviations and acronyms list (don't state in full in text).

Key messages
- Evaluative data on the long-term diabetes prevention effect of a single educational session for at risk people is lacking.

- The protective effect of attending the NHS-developed Walking Away from Diabetes (WAD) programme appears to be limited, though effectiveness analysis should take into account the role of confounding factors.

- More intense educational programmes have been introduced in the NHS recently; however, as for WAD their effectiveness should be measured with other variables (including e.g. high density lipid levels) taken into account.

**Abbreviations and acronyms list**

- HbA1C, haemoglobin A1C
- HDL, high density lipids
- HR, Hazard Ratio
- NHS, National Health Service
- T2DM, Type 2 diabetes mellitus
- WAD, Walking Away from Diabetes
Table 1, baseline demographics and clinical measures for patients referred to Walking Away from Diabetes programme.

| Variable                              | WAD attenders (n = 3470) | WAD non-attenders (n = 2646) | p-value |
|---------------------------------------|--------------------------|------------------------------|---------|
| Age, years, mean (95% CI)             | 66 (66-67)               | 63 (63-64)                   | <0.001~ |
| Sex, n, male / female (%)             | 1527 / 1943 (44% / 56%)  | 1228 / 1418 (46% / 54%)      | 0.061*  |
| Index of Multiple Deprivation, decile, median (95% CI) | 6 (5.81-5.98) | 6 (5.44-5.64) | <0.001~ |
| HbA1C, mmol/mol, mean                 | 44.2                     | 44.2                         | 0.16~   |
Blood pressure systolic, mmHg, mean (95% CI) 133.9 (133.4-134.4) 133.9 (133.3-134.5) 0.81~

Blood pressure diastolic, mmHg, mean (95% CI) 78.1 (77.7-78.4) 78.4 (78.0-78.8) 0.30~

HDL, mmol/L, mean (95% CI) 1.48 (1.46-1.50) 1.43 (1.41-1.45) <0.001~

Total Cholesterol, mmol/L, mean (95% CI) 4.91 (4.86-4.95) 4.99 (4.84-5.04) 0.007~

#Chi-squared test; ~Mann-Whitney U-test; 95% CI, 95% confidence interval

Table 2, Cox regression analysis for diabetes as outcome and follow-up in months as time factor.

| Variable                                      | Hazard Ratio | 95% CI       | p-value |
|-----------------------------------------------|--------------|--------------|---------|
| Deprivation index rating (1 = most deprived, to 10 = least deprived) | 0.97         | 0.94 – 0.99  | 0.018*  |
| Patient sex (0 = male; 1 = female)            | 1.16         | 0.99 – 1.35  | 0.056   |
| Patient age (years)                            | 0.99         | 0.98 – 1.00  | 0.019*  |
| WAD attendance (0 = non-attendance; 1 = attendance) | 0.89         | 0.77 – 1.03  | 0.11    |
| Blood pressure systolic (mmHg)                | 1.00         | 0.99 – 1.01  | 0.78    |
| Variable                       | Value 1 | Value 2     | p-value |
|-------------------------------|---------|-------------|---------|
| Blood pressure diastolic (mmHg) | 1.01    | 0.99 – 1.01 | 0.31    |
| HbA1C (mmol / mol)             | 1.23    | 1.21 – 1.24 | <0.001* |
| HDL (mmol/L)                   | 0.67    | 0.56 – 0.81 | <0.001* |
| Cholesterol (mmol/L)           | 0.91    | 0.86 – 0.96 | 0.001*  |

*Statistically significant, p-value <0.05. HR score of > 1 indicates that increased value for variable is associated with increased risk of developing diabetes; conversely, HR of < 1 indicates that increased value of variable is associated with decreased risk of developing diabetes.